RADIODIAGNOSIS OF SCCL WITH ANTIBODIES TO NEUROPHYSINS
使用神经物理素抗体对 SCCL 进行放射诊断
基本信息
- 批准号:3189838
- 负责人:
- 金额:$ 10.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1988
- 资助国家:美国
- 起止时间:1988-04-01 至 1993-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The purpose of this project is to determine the contribution that
antibodies to human neurophysins can make to radiodiagnosis of
small-cell carcinoma of the lung (SCCL). Human neurophysins
(HNPs) are produced by most SCCL tumors, and this persistent
property leads to the generation of surface makers (neurophysin-
related antigens, NPRA) that are recognized by antibodies to
HNPs. Pilot studies conducted with 131 I-labelled forms of these
antibodies indicate they can be employed to effectively
radioimage SCCL in all patients with HNP-producing tumors.
Specific Aims are directed towards: (i) performing a
comprehensive evaluation of 131 I-labelled polyclonal anti-HNPs
as radiodiagnostic agents for SCCL with respect to their provision
of a sensitive, specific, and informative method of tumor imaging
that complements standard methods of diagnosis; (ii) appraising
available monoclonal anti-HNPs (and their Fab, Fab' and F(ab')2
fragments) for possible clinical application based on their
capacity to bind to SCCL cells in vitro, their ability to provide
clear radioimages of tumor xenografts in athymic mice, their
specificity for tumor cells, and their biodistribution of clearance;
(iii) conducting patient studies with a radiolabelled preparation
and monoclonal anti-HNP chosen from animal studies for its
potential clinical utility; and (iv) applying our knowledge of HNP
biosynthesis and tumor vascular resistance to develop improved
methods for radioimaging SCCL tumors with anti-HNPs.
Concurrent clinical investigations with polyclonal antibodies and
animal studies on monoclonal antibody evaluation will precede the
experimental use of monoclonal antibodies in patients and those
studies on pharmacological manipulation designed to improve
delivery of radionuclide to tumors. Quantitative information on
tumor binding of radionuclides, tissue dosimetry, and the tumor
specificity of our antibodies will be obtained by gamma-camera
bidirectional scintigraphy, radiometric analysis and
immunocytochemistry. Antibody binding in vitro will be assessed
by cytofluorometry and radiometric analysis. A chronically
catheterized conscious rat preparation will be employed for
biodistribution and clearance studies.
The proposed research is expected to lead not only to the adoption
of anti-HNPs as valuable diagnostic agents, but also to their
eventual use in the therapeutic management of SCCL.
该项目的目的是确定
抗人神经垂体后叶素的抗体对放射诊断
肺小细胞癌(SCCL) 人神经垂体素
(HNP)是由大多数SCCL肿瘤产生的,这种持续的
属性导致表面制造商(neurophysin,
相关抗原,NPRA),这些抗原被抗体识别,
HNP。 用131 I标记的这些形式进行了初步研究
抗体表明它们可以有效地
放射成像SCCL在所有HNP产生肿瘤的患者。
具体目标是:(一)执行一项
131 I标记的多克隆抗HNP的综合评价
作为SCCL的放射诊断剂,
一种灵敏、特异、信息丰富的肿瘤成像方法,
补充标准诊断方法;(二)评估
可用的单克隆抗HNP(及其Fab、Fab'和F(ab')2
片段)用于可能的临床应用,
体外结合SCCL细胞的能力,它们提供
无胸腺小鼠中肿瘤异种移植物的清晰放射图像,
对肿瘤细胞的特异性及其清除的生物分布;
(iii)使用放射性标记制剂进行患者研究
和从动物研究中选择的单克隆抗HNP,
潜在的临床效用;及(iv)运用我们对HNP的知识
生物合成和肿瘤血管阻力发展改善
用抗HNP对SCCL肿瘤进行放射成像的方法。
同时进行多克隆抗体和
单克隆抗体评价的动物研究将先于
单克隆抗体在患者和那些
药理学研究旨在改善
将放射性核素递送到肿瘤。 的定量信息
放射性核素的肿瘤结合、组织剂量测定和肿瘤
我们的抗体的特异性将通过伽马照相机获得
双向层析成像、放射性分析和
免疫细胞化学 将评估体外抗体结合
通过细胞荧光和放射性分析。 一个慢性
将采用插管的清醒大鼠制备物用于
生物分布和清除研究。
预计拟议的研究不仅会导致采用
抗HNP作为有价值的诊断剂,但也对其
最终用于SCCL的治疗管理。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Neuropeptide production by small cell carcinoma: vasopressin and oxytocin as plasma markers of disease.
小细胞癌产生的神经肽:加压素和催产素作为疾病的血浆标志物。
- DOI:10.1210/jcem-73-6-1316
- 发表时间:1991
- 期刊:
- 影响因子:0
- 作者:North,WG
- 通讯作者:North,WG
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WILLIAM G NORTH其他文献
WILLIAM G NORTH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WILLIAM G NORTH', 18)}}的其他基金
NMDA receptors in the diagnosis and treatment of pancreatic cancer
NMDA受体在胰腺癌诊断和治疗中的作用
- 批准号:
8705474 - 财政年份:2013
- 资助金额:
$ 10.7万 - 项目类别:
NMDA receptors in the diagnosis and treatment of pancreatic cancer
NMDA受体在胰腺癌诊断和治疗中的作用
- 批准号:
8445025 - 财政年份:2013
- 资助金额:
$ 10.7万 - 项目类别:
NMDA receptors in the diagnosis and treatment of breast cancer
NMDA受体在乳腺癌诊断和治疗中的应用
- 批准号:
7787905 - 财政年份:2010
- 资助金额:
$ 10.7万 - 项目类别:
NMDA receptors in the diagnosis and treatment of breast cancer
NMDA受体在乳腺癌诊断和治疗中的应用
- 批准号:
8011719 - 财政年份:2010
- 资助金额:
$ 10.7万 - 项目类别:
NMDA receptors in the diagnosis and treatment of small cell lung cancer.
NMDA 受体在小细胞肺癌诊断和治疗中的应用。
- 批准号:
7389439 - 财政年份:2008
- 资助金额:
$ 10.7万 - 项目类别:
NMDA receptors in the diagnosis and treatment of small cell lung cancer.
NMDA 受体在小细胞肺癌诊断和治疗中的应用。
- 批准号:
7578934 - 财政年份:2008
- 资助金额:
$ 10.7万 - 项目类别:
VP peptides and receptors in diagnosis of breast cancer.
VP 肽和受体在乳腺癌诊断中的应用。
- 批准号:
7140097 - 财政年份:2005
- 资助金额:
$ 10.7万 - 项目类别:
VP peptides and receptors in diagnosis of breast cancer.
VP 肽和受体在乳腺癌诊断中的应用。
- 批准号:
6966384 - 财政年份:2005
- 资助金额:
$ 10.7万 - 项目类别:
GRSA Proteins in the Diagnosis of Breast Cancer
GRSA 蛋白在乳腺癌诊断中的应用
- 批准号:
6515212 - 财政年份:2001
- 资助金额:
$ 10.7万 - 项目类别:
GRSA Proteins in the Diagnosis of Breast Cancer
GRSA 蛋白在乳腺癌诊断中的应用
- 批准号:
6368569 - 财政年份:2001
- 资助金额:
$ 10.7万 - 项目类别:














{{item.name}}会员




